In light of debate within American society on the topic of stem cell research, the JCPA adopted a resolution on therapeutic cloning research in 2004.  The following clarifies the scientific content of that policy’s action recommendations:

 

The community relations field should:

  1. Research using embryonic stem cells including those developed through Somatic Cell Nuclear Transfer (SCNT);
  2. Government funding for such research;
  3. Efforts by the scientific community to develop regulations and monitor those using SCNT technology;
  4. Appropriate legislative actions consistent with the above objectives, including legislation that encourages the development of new stem cell lines in addition to the existing stem cell lines already approved for funding by the federal government;
  5. The creation of a fully funded and empowered oversight body comprising of scientists and ethicists to monitor this research, paying special attention to ensuring that the research is restricted to stem cells of very early embryonic development, prior to implantation in a uterus.
 
Share

Next Up:

Court Stripping

Take Action Donate

April 7, 2026

JCPA Condemns U.S. Presidential Threat to Destroy Iranian “Civilization”

April 1, 2026

JCPA Statement as SCOTUS Hears Arguments in Birthright Citizenship Case

March 30, 2026

2026 Haggadah Supplement

March 24, 2026

JCPA Statement on Markwayne Mullin DHS Secretary Confirmation

March 16, 2026

ICYMI: JCPA’s Amy Spitalnick Speaks on the Attack at Michigan’s Temple Israel

March 12, 2026

JCPA Statement on Synagogue Attack in West Bloomfield, MI

March 6, 2026

One Year In: A Look at the Administration’s Approach to Antisemitism

March 5, 2026

JCPA statement on Kristi Noem’s departure from the Department of Homeland Security

February 25, 2026

J Weekly: JCPA head seeks to reset coalition building post-Oct. 7, Gaza war

February 19, 2026

Jewish Safety ‘Inextricably Linked With Democracy,’ JCPA CEO Amy Spitalnick Tells U.S. Commission on Civil Rights